← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
DuPont is smaller after Qnity, with modest growth and a reported net loss.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +1.9% to $6.85BNote
- Profitability — Net income -210.8%; loss yearWatch
- Margins — Gross +146 bps; net -2183 bpsNote
- Capital — Capex +16.8%; dividends -6.0%Watch
- Balance sheet — Debt -41.1%; equity -40.4%Note
- Accounting — Low Z screen; no Beneish flagWatch
- Insiders — 0 buys / 6 sellsWatch
Business
DuPont now presents itself as an advanced materials and specialty technologies company focused on healthcare, water, construction, and industrial markets after the separation of its electronics business into Qnity.
Where the revenue comes from
Fiscal 2025, as DuPont de Nemours, Inc. reports it. History and quarterly detail are in the app.
- Diversified Industrials$3.6B
- Healthcare & Water Technologies$3.2B
Leadership changes
From DuPont de Nemours, Inc.'s own filings, the day they're filed.
- Luke Kissam · member · departureeff. 2026-04-14
- G. Macpherson · Directors · appointmenteff. 2026-01-20
- Kristina M. Johnson · Directors · departureeff. 2025-11-01
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-05-26
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about DuPont de Nemours, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.